FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308030532> ?p ?o ?g. }

• W4308030532 endingPage "300" @default.
• W4308030532 startingPage "291" @default.
• W4308030532 abstract "Although published data have supported the use of hypofractionated regional nodal irradiation (HF-RNI) for breast cancer, limited dosimetric data exist to evaluate predictors of lung toxicity. The ongoing RT CHARM trial limits the percentage of ipsilateral lung volume that receives ≥18 Gy to 35 to 40%. We assessed dosimetry, toxicity, and disease outcomes in patients with breast cancer treated with HF-RNI with a particular focus on pneumonitis.We retrospectively reviewed all patients with breast cancer treated with HF-RNI (40-43 Gy in 15-16 fractions) after either lumpectomy or mastectomy at The University of Pittsburgh Medical Center from September 2018 to December 2021 to collect dosimetric and outcomes data. All post-radiation therapy chest computed tomography (CT) scans were manually reviewed for evidence of acute (≤6 months postradiation) or chronic (>6 months postradiation) pneumonitis.One-hundred-ninety-one patients qualified with a median follow-up of 20.3 months (range, 5.1-42.2). Acute grade 1 (G1) pneumonitis was observed in 6.8% of the overall cohort (13 of 191 patients) and 39.4% of the patients (13 of 33) who received a chest CT ≤6 months postradiation therapy. Only 1 patient developed acute G2 pneumonitis. Chronic G1 pneumonitis was observed in 29.8% of the overall cohort (57 of 191 patients) and 77% of patients (57 of 74 patients) who received a chest CT >6 months postradiation therapy. No patients developed acute G3+ or chronic G2+ pneumonitis.Rates of symptomatic pneumonitis were low in this cohort of patients treated with HF-RNI, even with integration of HER2/neu-directed therapy, chemotherapy, hormone therapy, and internal mammary nodal irradiation. Lung V20Gy <26% appeared safe in this cohort to limit symptomatic pneumonitis, though this is not meant to represent the safe upper limit. Given the low event rate of symptomatic pneumonitis, data from larger cohorts will be needed to assess dosimetric predictors and the safe upper limit of lung dose." @default.
• W4308030532 created "2022-11-07" @default.
• W4308030532 creator A5023468026 @default.
• W4308030532 creator A5030482195 @default.
• W4308030532 creator A5037244634 @default.
• W4308030532 creator A5068696005 @default.
• W4308030532 creator A5072837125 @default.
• W4308030532 creator A5075749228 @default.
• W4308030532 creator A5082714186 @default.
• W4308030532 creator A5083548567 @default.
• W4308030532 date "2023-07-01" @default.
• W4308030532 modified "2023-10-01" @default.
• W4308030532 title "Dosimetry and Toxicity Outcomes in Patients Treated with Hypofractionated Regional Nodal Irradiation for Breast Cancer: What is the Best Dose-Volume Limit to Minimize Risks of Radiation Pneumonitis?" @default.
• W4308030532 cites W1757759434 @default.
• W4308030532 cites W1844888674 @default.
• W4308030532 cites W1896027563 @default.
• W4308030532 cites W1977640569 @default.
• W4308030532 cites W1992823006 @default.
• W4308030532 cites W2036422623 @default.
• W4308030532 cites W2096499183 @default.
• W4308030532 cites W2103608035 @default.
• W4308030532 cites W2105361492 @default.
• W4308030532 cites W2133306253 @default.
• W4308030532 cites W2158831969 @default.
• W4308030532 cites W2554819881 @default.
• W4308030532 cites W2583036852 @default.
• W4308030532 cites W2611369172 @default.
• W4308030532 cites W2766334616 @default.
• W4308030532 cites W2768733244 @default.
• W4308030532 cites W2789698864 @default.
• W4308030532 cites W2793940682 @default.
• W4308030532 cites W2898962716 @default.
• W4308030532 cites W2904433568 @default.
• W4308030532 cites W2913181387 @default.
• W4308030532 cites W2983121453 @default.
• W4308030532 cites W3006116630 @default.
• W4308030532 cites W3016251848 @default.
• W4308030532 cites W3021410191 @default.
• W4308030532 cites W3047809007 @default.
• W4308030532 cites W3086878246 @default.
• W4308030532 cites W3093662369 @default.
• W4308030532 cites W3166684131 @default.
• W4308030532 cites W4226295831 @default.
• W4308030532 cites W4229005781 @default.
• W4308030532 cites W4280506554 @default.
• W4308030532 cites W993406450 @default.
• W4308030532 doi "https://doi.org/10.1016/j.prro.2022.10.007" @default.
• W4308030532 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36332799" @default.
• W4308030532 hasPublicationYear "2023" @default.
• W4308030532 type Work @default.
• W4308030532 citedByCount "0" @default.
• W4308030532 crossrefType "journal-article" @default.
• W4308030532 hasAuthorship W4308030532A5023468026 @default.
• W4308030532 hasAuthorship W4308030532A5030482195 @default.
• W4308030532 hasAuthorship W4308030532A5037244634 @default.
• W4308030532 hasAuthorship W4308030532A5068696005 @default.
• W4308030532 hasAuthorship W4308030532A5072837125 @default.
• W4308030532 hasAuthorship W4308030532A5075749228 @default.
• W4308030532 hasAuthorship W4308030532A5082714186 @default.
• W4308030532 hasAuthorship W4308030532A5083548567 @default.
• W4308030532 hasConcept C116263406 @default.
• W4308030532 hasConcept C121608353 @default.
• W4308030532 hasConcept C126322002 @default.
• W4308030532 hasConcept C126838900 @default.
• W4308030532 hasConcept C2777714996 @default.
• W4308030532 hasConcept C2779524853 @default.
• W4308030532 hasConcept C2781047374 @default.
• W4308030532 hasConcept C29730261 @default.
• W4308030532 hasConcept C2989005 @default.
• W4308030532 hasConcept C509974204 @default.
• W4308030532 hasConcept C530470458 @default.
• W4308030532 hasConcept C71924100 @default.
• W4308030532 hasConcept C72563966 @default.
• W4308030532 hasConceptScore W4308030532C116263406 @default.
• W4308030532 hasConceptScore W4308030532C121608353 @default.
• W4308030532 hasConceptScore W4308030532C126322002 @default.
• W4308030532 hasConceptScore W4308030532C126838900 @default.
• W4308030532 hasConceptScore W4308030532C2777714996 @default.
• W4308030532 hasConceptScore W4308030532C2779524853 @default.
• W4308030532 hasConceptScore W4308030532C2781047374 @default.
• W4308030532 hasConceptScore W4308030532C29730261 @default.
• W4308030532 hasConceptScore W4308030532C2989005 @default.
• W4308030532 hasConceptScore W4308030532C509974204 @default.
• W4308030532 hasConceptScore W4308030532C530470458 @default.
• W4308030532 hasConceptScore W4308030532C71924100 @default.
• W4308030532 hasConceptScore W4308030532C72563966 @default.
• W4308030532 hasIssue "4" @default.
• W4308030532 hasLocation W43080305321 @default.
• W4308030532 hasLocation W43080305322 @default.
• W4308030532 hasOpenAccess W4308030532 @default.
• W4308030532 hasPrimaryLocation W43080305321 @default.
• W4308030532 hasRelatedWork W1480041025 @default.
• W4308030532 hasRelatedWork W1780987068 @default.
• W4308030532 hasRelatedWork W1977428742 @default.
• W4308030532 hasRelatedWork W1994581662 @default.
• W4308030532 hasRelatedWork W2021910092 @default.
• W4308030532 hasRelatedWork W2050995202 @default.
• W4308030532 hasRelatedWork W2091724184 @default.

• next